跳至主要内容
临床试验/NCT05342493
NCT05342493招募中不适用

AJOVY Subcutaneous Injection Long-term Specified Use-results Survey

Otsuka Pharmaceutical Co., Ltd.2 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2022年4月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
1,000
试验地点
2
主要终点
Safety information (Adverse Event)

研究概览

简要总结

To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • patients with a known hypersensitivity to components of AJOVY

研究组 & 干预措施

Drug

Ajovy syringe for SC injection 225 mg.

干预措施: Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution (Drug)

结局指标

主要结局

Safety information (Adverse Event)

时间窗: 2 years from the start date of treatment

Any untoward medicinal occurrence in a patient or clinical study subject administered a Medicinal Product and which does not necessarily have a causal relationship with this treatment (see Annex Ⅳ, ICH-E2A Guideline). An Adverse Event can therefore be any unfavorable and unintended sign (e.g. abnormal laboratory finding), symptom, or disease temporally associated with the use of a Medicinal Product, whether or not it is considered causally related to the Medicinal Product.

Number of Special Situations

时间窗: 2 years from the start date of treatment

Collecting any Situations related to the use of an Otsuka product which may or may not be associated with an adverse event: * Maternal (pregnancy and breastfeeding) or paternal (via semen) exposure; * Exposure during breastfeeding; * Overdose/Incorrect dosage, misuse, abuse (e.g. patient sharing products); * Medication errors (e.g. patient took wrong dose); * Lack of therapeutic efficacy (e.g. the product doesn't work); * Occupational exposure (e.g.: nurse administering the product is exposed); * Cases of suspected transmission of infectious agents; * Use of suspected or confirmed falsified product(s) or quality defect of the product(s); * Withdrawal reactions; * Accidental exposure (e.g.: child takes parent's product); * Drug-drug/drug-food interactions; * Unintentional use of product in a non-approved population (e.g.: pediatric or geriatric population); * Disease progression/exacerbation of existing disease

Number of off-Label Use

时间窗: 2 years from the start date of treatment

Collecting any type of off-Label Use that refers to situations where a product is intentionally used for a medical purpose not in accordance with the authorized product information. Off-label use also includes the intentional use in non-authorized population categories not indicated in the label.

Incidence of Serious Adverse Event (e.g. resulting in death or life-threatening)

时间窗: 2 years from the start date of treatment

Collecting the number of any adverse drug experience/event occurring at any dose which * results in death * is life-threatening * requires inpatient hospitalization or prolonged of existing hospitalization * results in persistent or significant disability or incapacity * is a congenital anomaly/birth defect * is medically significant.

Incidence of Non-serious Adverse Events (i.e. all Adverse Events that do not meet the definition of a serious Adverse Event)

时间窗: 2 years from the start date of treatment

Collecting the number of non-serious Adverse Events

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验